Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who are largely able to care for themselves day-to-day, with only occasional help from others
• People who have a confirmed diagnosis of a neuroendocrine tumor originating in the gastrointestinal tract, pancreas, or chest with specific tumor growth markers (ki67 greater than 20%), or a neuroendocrine carcinoma from any part of the body — excluding small cell lung cancer
• People whose cancer has shown clear signs of growth or spread on at least two scans (CT or MRI) taken at least four weeks apart, within the past twelve months
• People whose cancer has already been treated with at least one prior systemic (whole-body) treatment that did not fully work
• People currently taking somatostatin analogue medications, as these may generally be continued during the trial (confirm with trial site)
• People whose stored tumor tissue has tested positive for a protein called survivin, confirmed by laboratory testing before joining the trial
• People with blood test results within the past 14 days showing healthy enough levels of white blood cells, platelets, and red blood cells (confirm specific values with trial site)
• People with liver and kidney function results within acceptable ranges, based on blood tests taken within the past 14 days (confirm specific values with trial site)
• People taking blood-thinning medications (such as warfarin or heparin) who have no active bleeding and no condition considered high-risk for bleeding, in the treating doctor's opinion
• People of childbearing potential who agree to use adequate contraception throughout the study, and who agree to inform their treating doctor immediately if pregnancy occurs or is suspected
• People who understand the investigational nature of this study and have signed a written consent form approved by an ethics committee before any study procedures begin

Who may not be able to join:

• People who previously received a chemotherapy drug called temozolomide for advanced disease and whose cancer got worse while taking it
• People who have previously received the study treatment, SurVaxM
• People who have received any other experimental treatment within the 30 days before joining
• People who have received immune checkpoint inhibitor therapy within the 3 months before joining, or who have not yet recovered from side effects of such treatments
• People with uncontrolled ongoing illness — such as active infection, heart failure, unstable chest pain, irregular heartbeat, abnormal heart rate, or mental health or personal circumstances that could make it difficult to safely follow the study requirements
• People with a current or previous cancer diagnosis, unless that cancer was either a non-invasive skin condition or a type of skin cancer (basal cell carcinoma) that was fully treated, or unless the person has been cancer-free for at least 3 years
• People with a known history of an autoimmune condition
• People known to have HIV, AIDS-related illness, or other serious medical illness
• People taking corticosteroid medications (such as dexamethasone) at a daily dose above a certain threshold at the time of study entry (confirm specific dose with trial site)
• People who are pregnant or breastfeeding
• People who are unwilling or unable to follow the study's requirements
• People whom the trial investigator considers unsuitable to receive the study treatment for any reason
• People with Hepatitis B or Hepatitis C whose viral levels are not adequately controlled, or where there may be interactions with other medications (those with well-controlled levels may potentially be included — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.